HIMS Hims & Hers Health
- 13.840
- +0.100+0.73%
- 13.790
- -0.050-0.36%
Hims & Hers Health News
Analysts Offer Insights on Healthcare Companies: Avita Medical (RCEL), Inotiv (NOTV) and Hims & Hers Health (HIMS)
Deutsche Bank Adjusts Hims & Hers Health Price Target to $16 From $14, Maintains Hold Rating
Buy Rating Affirmed for Hims & Hers Health Amidst Strong Quarterly Performance and Positive Outlook
Hims & Hers Health Analyst Ratings
Piper Sandler Maintains Neutral on Hims & Hers Health, Raises Price Target to $13
Jefferies Investment Bank: Downgraded the Hims & Hers Health (HIMS.US) rating from buy to hold, and the target price was adjusted from $17.00 to $15.00.
Hims & Hers Health Analyst Ratings
Hims & Hers Health (HIMS.US) was first covered by the Canadian Investment Banking Group, giving it a buying rating, with a target price of $20.00.
Hims & Hers Health Analyst Ratings
Hims & Hers Health Outperforms: Strong Sales Growth and Brand Value Reinforce Buy Rating
Analysts Offer Insights on Healthcare Companies: Regulus (RGLS), Hims & Hers Health (HIMS) and Olink Holding (OLK)
Tigress Financial Boosts Price Target on Hims & Hers Health to $19 From $15, Cites Move to Accelerated Growth Phase, Keeps Buy Rating
Analysts Conflicted on These Healthcare Names: ACADIA Pharmaceuticals (ACAD), Hims & Hers Health (HIMS) and Amylyx Pharmaceuticals Inc (AMLX)
Deutsche Bank Adjusts Hims & Hers Health Price Target to $14 From $8, Maintains Hold Rating
Hims & Hers Health Analyst Ratings
Analysts Are Bullish on Top Healthcare Stocks: Bruker (BRKR), Hims & Hers Health (HIMS)
Truist Financial Reaffirms Their Hold Rating on Hims & Hers Health (HIMS)
Hims & Hers Health (HIMS) Gets a Hold From Piper Sandler
Leerink Partners Initiates Coverage On Hims & Hers Health With Market Perform Rating, Announces Price Target of $10
Hims & Hers Health Analyst Ratings
Analysis
Price Target
No Data
